Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
68.3(c) 69.1(c) 68.38(c) 70(c) 69.66 Last
257 443 447 558 360 702 443 568 106 453 Volume
+0.86% +1.17% -1.04% +2.37% -0.49% Change
More quotes
Financials (€)
Sales 2017 4 394 M
EBIT 2017 1 019 M
Net income 2017 667 M
Debt 2017 516 M
Yield 2017 1,77%
Sales 2018 4 557 M
EBIT 2018 1 115 M
Net income 2018 769 M
Debt 2018 27,3 M
Yield 2018 1,87%
P/E ratio 2017 19,20
P/E ratio 2018 16,96
EV / Sales2017 3,22x
EV / Sales2018 2,99x
Capitalization 13 615 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.The company was founded by Emmanuel Janssen on January 18, 1928 and is... 
Sector
Pharmaceuticals
Calendar
02/22 | 07:00amEarnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
01/19 UCB S.A. REPORTS FINDINGS IN PARKINS : A randomized,...
01/12 Pfizer's Barrett named CEO of Novartis Oncology
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
01/09 UCB : European Medicines Agency Accepts Filing for EVENITYTM
01/04 DATA ON PSORIATIC ARTHRITIS DISCUSSE : ...
2017 European stocks sink on Flynn guilty plea after choppy session
2017 European stocks sink on Flynn guilty plea after choppy session
2017 UCB : Research Conducted at UCB S.A. Has Provided New Information about Clinical..
2017 UCB : New study data shows prior osteoporotic fractures put women at increased r..
2017 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
More news
Sector news : Pharmaceuticals - NEC
07:58a Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion
07:58a Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion
07:47a SANOFI : to Acquire Bioverativ for $11.6 Billion
03:22a SANOFI SET TO BUY BIOVERATIV FOR MOR : Wsj
02:53a SANOFI : Nears Deal to Buy Hemophilia Drugmaker Bioverativ for More Than $11.5 B..
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on UCB 
UCB - 2017
After the accumulation, an upward acceleration ?
BUY
UCB - 2017
Close to a key level on the weekly chart
BUY
More Strategies
Latest Tweets
01/19Improv is labor. So why doesn't UCB pay its performers?
4
01/19Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report.. 
01/19Jefferies Group Sets UCB FY2017 Earnings Estimates at $5.23 EPS.  
01/19Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report..
8
01/18UCB investigated an employee for sexual misconduct, but wouldn't tell the stu..
7
More tweets
Qtime:58
News from SeekingAlpha
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
01/08 EMA accepts UCB's marketing application for osteoporosis med romosozumab
2017 Dermira to returns rights to psoriasis candidate Cimzia back to UCB; shares d..
2017 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 67,1 €
Spread / Average Target -4,1%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB5.77%16 637
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132